Professor Jeff Evans

  • Director of Institute/Professor of Translational Cancer Research (Experimental Therapeutics)

Personal assistant: Miss Fiona Conway
telephone: 01413304890
email: Fiona.Conway@glasgow.ac.uk

Research interests

Clinical

My clinical research interests are in the pre-clinical and clinical development of novel anti-cancer agents including molecular targeted therapies and gene therapy. I run a number of Phase 1 clinical trials of innovative anti-cancer agents, and I also run the Analytical Services Unit at the Centre for Oncology and Applied Pharmacology, University of Glasgow. My clinical research interests also include the development of novel therapies for gastro-oesophageal and hepato-biliary-pancreatic cancers and melanoma.

Laboratory

Current strategies in the development of novel therapies are based on exploiting our increasing understanding of the molecular basis of cancer. The classical paradigm for developing cancer therapeutics is dependent on demonstrating a reduction in tumour size on serial clinical or radiological assessments as an indication of anti-tumour activity. However tumour volume is a complex integral of growth, involution, necrosis and inflammatory processes, and so volume alone is not the most appropriate parameter in determining response. Coupled with this, the current generation of molecular-targeted therapies have been designed to inhibit specific molecular processes and may not consistently result in objective tumour reduction in patients with advanced refractory tumours despite producing their desired biological effect. My group is attempting to overcome this problem by developing novel laboratory models that allows us to determine how potentially anti-invasive agents might best be evaluated in subsequent clinical trials, and by developing bio-markers of anti-tumour activity to specific agents that can be applied to biological samples collected from patients in clinical trials of novel anti-cancer agents.

Link to Translational Cancer Therapeutics website


Publications

List by: Type | Date

Jump to: 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001
Number of items: 121.

2019

Jones, R. L. et al. (2019) Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European Journal of Cancer, 120, pp. 132-139. (doi:10.1016/j.ejca.2019.07.024) (PMID:31522033)

Naumann, R. W. et al. (2019) Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial. Journal of Clinical Oncology, (Accepted for Publication)

Reader, C. S. et al. (2019) The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, (doi:10.1002/path.5320) (PMID:31259422) (Early Online Publication)

Evans, T. R. J. et al. (2019) Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. British Journal of Cancer, (doi:10.1038/s41416-019-0506-6) (Early Online Publication)

Neves, K. B. , Rios, F. J. , Jones, R. , Evans, T. R. J. , Montezano, A. C. and Touyz, R. M. (2019) Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury. Cardiovascular Research, 115(5), pp. 978-988. (doi:10.1093/cvr/cvz021) (PMID:30753341) (PMCID:PMC6452312)

Conway, J. R.W., Herrmann, D., Evans, T.R. J. , Morton, J. P. and Timpson, P. (2019) Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut, 68(4), pp. 742-758. (doi:10.1136/gutjnl-2018-316822) (PMID:30396902) (PMCID:PMC6580874)

Twelves, C. et al. (2019) A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer, 120(6), pp. 579-586. (doi:10.1038/s41416-018-0366-5) (PMID:30783204) (PMCID:PMC6461928)

Anderson, R. L. et al. (2019) A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 16(3), pp. 185-204. (doi:10.1038/s41571-018-0134-8) (PMID:30514977)

Evans, T.R. J. et al. (2019) Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. British Journal of Cancer, (doi:10.1038/s41416-019-0377-x)

2018

Janjigian, Y. Y. et al. (2018) CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. Journal of Clinical Oncology, 36(28), pp. 2836-2844. (doi:10.1200/JCO.2017.76.6212) (PMID:30110194) (PMCID:PMC6161834)

Lindsay, C. R. et al. (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3(6), e000408. (doi:10.1136/esmoopen-2018-000408) (PMID:30233821) (PMCID:PMC6135448)

Basu, B. et al. (2018) Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology, 29(9), pp. 1918-1925. (doi:10.1093/annonc/mdy245) (PMID:30016392) (PMCID:PMC6158767)

Krol, I. et al. (2018) Detection of circulating tumor cell clusters in human glioblastoma. British Journal of Cancer, 119, pp. 487-491. (doi:10.1038/s41416-018-0186-7) (PMID:30065256)

Baxter, M.A., Glen, H. and Evans, T.R.J. (2018) Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma. Future Oncology, 14(20), pp. 2021-2029. (doi:10.2217/fon-2017-0689) (PMID:29783903)

Candido, J. B. et al. (2018) CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Reports, 23(5), pp. 1448-1460. (doi:10.1016/j.celrep.2018.03.131) (PMID:29719257)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R. and Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicological Sciences, 163(1), pp. 293-306. (doi:10.1093/toxsci/kfy035) (PMID:29462473) (PMCID:PMC5920327)

Carvajal, R. D. et al. (2018) Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicentre, randomised trial (SUMIT). Journal of Clinical Oncology, 36(12), pp. 1232-1239. (doi:10.1200/JCO.2017.74.1090) (PMID:29528792)

Kudo, M. et al. (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 391(10126), pp. 1163-1173. (doi:10.1016/S0140-6736(18)30207-1) (PMID:29433850)

Marchetti, C. et al. (2018) Targeting multiple effector pathways in pancreatic ductal adenocarcinoma with a G-quadruplex-binding small molecule. Journal of Medicinal Chemistry, 61(6), pp. 2500-2517. (doi:10.1021/acs.jmedchem.7b01781) (PMID:29356532)

Cook, N. et al. (2018) A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 118(6), pp. 793-801. (doi:10.1038/bjc.2017.495) (PMID:29438372) (PMCID:PMC5877439)

Wilson, R. A.M., Evans, T.R. J. , Fraser, A. R. and Nibbs, R. J.B. (2018) Immune checkpoint inhibitors: new strategies to checkmate cancer. Clinical and Experimental Immunology, 191(2), pp. 133-148. (doi:10.1111/cei.13081) (PMID:29139554)

2017

Meyer, T. et al. (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterology and Hepatology, 2(8), pp. 565-575. (doi:10.1016/S2468-1253(17)30156-5) (PMID:28648803)

de la Cruz-Merino, L. et al. (2017) Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of Translational Medicine, 15, 146. (doi:10.1186/s12967-017-1246-0) (PMID:28646893) (PMCID:PMC5483259)

Vennin, C. et al. (2017) Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9(384), eaai8504. (doi:10.1126/scitranslmed.aai8504) (PMID:28381539) (PMCID:PMC5777504)

Wilson, R. H. et al. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116(884), (doi:10.1038/bjc.2017.36) (PMID:28222073)

Evans, T.R.J. et al. (2017) Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Annals of Oncology, 28(2), pp. 354-361. (doi:10.1093/annonc/mdw607) (PMID:27998964)

2016

Soria, J.C. et al. (2016) A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Annals of Oncology, 27(12), pp. 2268-2274. (doi:10.1093/annonc/mdw427) (PMID:27733373)

Driscoll, D. R. et al. (2016) mTORC2 signaling drives the development and progression of pancreatic cancer. Cancer Research, 76(23), pp. 6911-6923. (doi:10.1158/0008-5472.CAN-16-0810) (PMID:27758884)

Edeline, J. et al. (2016) A multicenter comparison between Child Pugh and ALBI scores in patients treated with sorafenib for hepatocellular carcinoma. Liver International, 36(2), pp. 1821-1828. (doi:10.1111/liv.13170) (PMID:27214151)

Jamieson, D. et al. (2016) A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 68, pp. 1-10. (doi:10.1016/j.ejca.2016.08.026) (PMID:27693888)

Propper, D., Jones, K., Anthoney, D. A., Mansoor, W., Ford, D., Eatock, M., Agarwal, R., Inatani, M., Saito, M. and Evans, T.R. J. (2016) Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. BMC Cancer, 16, 779. (PMID:27724887) (PMCID:PMC5057500)

Zhu, A. X. et al. (2016) Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with Sorafenib with or without Erlotinib in the SEARCH Trial. Clinical Cancer Research, 22(19), pp. 4870-4879. (doi:10.1158/1078-0432.CCR-15-2883) (PMID:27220960)

Aparicio, T., Zaanan, A., Mary, F., Afchain, P., Manfredi, S. and Evans, T. R. J. (2016) Small bowel adenocarcinoma. Gastroenterology Clinics of North America, 45(3), pp. 447-457. (doi:10.1016/j.gtc.2016.04.004) (PMID:27546842)

Bilsland, A. E. , Spiliopoulou, P. and Evans, T.R. J. (2016) Virotherapy: cancer gene therapy at last? F1000Research, 5, 2105. (doi:10.12688/f1000research.8211.1) (PMID:27635234) (PMCID:PMC5007754)

Antonia, S. J. et al. (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncology, 17(7), pp. 883-895. (doi:10.1016/S1470-2045(16)30098-5) (PMID:27269741)

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29(6), pp. 832-845. (doi:10.1016/j.ccell.2016.04.014) (PMID:27265504) (PMCID:PMC4912354)

Milojkovic Kerklaan, B. et al. (2016) A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Investigational New Drugs, 34(3), pp. 329-337. (doi:10.1007/s10637-016-0344-9) (PMID:27039386)

Graham, J.S., Boyd, K., Coxon, F.Y., Wall, L.R., Eatock, M.M., Maughan, T.S., Highley, M., Soulis, E., Conway, F. and Evans, T. (2016) A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Research Notes, 9(161), (doi:10.1186/s13104-015-1778-4) (PMID:26969121) (PMCID:PMC4788848)

Erami Rud Majani, Z. et al. (2016) Intravital FRAP imaging using an E-cadherin-GFP mouse reveals disease- and drug-dependent dynamic regulation of cell-cell junctions in live tissue. Cell Reports, 14(1), pp. 152-167. (doi:10.1016/j.celrep.2015.12.020) (PMID:26725115)

Carotenuto, P. et al. (2016) Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 66(7), pp. 1268-1277. (doi:10.1136/gutjnl-2016-312278) (PMID:27618837) (PMCID:PMC5530482)

2015

Venugopal, B., Awada, A., Evans, T.R.J. , Dueland, S., Hendlisz, A., Rasch, W., Hernes, K., Hagen, S. and Aamdal, S. (2015) A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 76(4), pp. 785-792. (doi:10.1007/s00280-015-2846-0) (PMID:26289594)

Steele, C. et al. (2015) CXCR2 inhibition suppresses acute and chronic pancreatic inflammation. Journal of Pathology, 237(1), pp. 85-97. (doi:10.1002/path.4555) (PMID:25950520)

Zhu, A.X. et al. (2015) SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, 33(6), pp. 559-566. (doi:10.1200/JCO.2013.53.7746) (PMID:25547503)

Evans, T. J. (2015) Small colony variants of Pseudomonas aeruginosa in chronic bacterial infection of the lung in cystic fibrosis. Future Microbiology, 10(2), pp. 231-239. (doi:10.2217/fmb.14.107) (PMID:25689535)

Puzanov, I. et al. (2015) A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clinical Cancer Research, 21(4), pp. 701-711. (doi:10.1158/1078-0432.CCR-14-0303) (PMID:25212606)

Hartmann, D., von Figura, G., Song, Z., Harden, S., Scott, L. C., Evans, T. J. , Rudolph, K. L., Bilsland, A. E. and Keith, W. N. (2015) PlasmaN-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome. Future Oncology, 11(2), pp. 193-203. (doi:10.2217/fon.14.166)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

Monsieurs, K. G. et al. (2015) European Resuscitation Council Guidelines for Resuscitation 2015. Section 1. Executive summary. Resuscitation, 95, pp. 1-80. (doi:10.1016/j.resuscitation.2015.07.038) (PMID:26477410)

2014

Moreno Garcia, V. et al. (2014) Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) collaboration study. Clinical Cancer Research, 20(22), pp. 5663-5671. (doi:10.1158/1078-0432.CCR-14-0719)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi:10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Roxburgh, P. , Lumsden, G. R., Paul, J. , Harden, S., Sweeting, L., James, A., Crellin, A., Morrison, R., Evans, T. R. J. and McDonald, A. C. (2014) A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 74(1), pp. 131-139. (doi:10.1007/s00280-014-2470-4) (PMID:24819683)

Middleton, G. et al. (2014) Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, 15(8), pp. 829-840. (doi:10.1016/S1470-2045(14)70236-0)

Chang, D. K. , Grimmond, S. M., Evans, T. R.J. and Biankin, A. V. (2014) Mining the genomes of exceptional responders. Nature Reviews Cancer, 14(5), pp. 291-292. (doi:10.1038/nrc3723) (PMID:25688402)

2013

Poplin, E. et al. (2013) Randomized, multicenter, phase 2 study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. Journal of Clinical Oncology, 31(35), pp. 4453-4461. (doi:10.1200/JCO.2013.51.0826)

Venugopal, B. et al. (2013) A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clinical Cancer Research, 19(15), pp. 4262-4272. (doi:10.1158/1078-0432.CCR-13-0312)

Steele, C.W., Jamieson, N.B. , Evans, T.R.J. , McKay, C.J., Sansom, O.J. , Morton, J. and Carter, C.R. (2013) Exploiting inflammation for therapeutic gain in pancreatic cancer. British Journal of Cancer, 108(5), pp. 997-1003. (doi:10.1038/bjc.2013.24)

Macpherson, I.R. , Poondru, S., Simon, G.R., Gedrich, R., Brock, K., Hopkins, C.A., Stewart, K., Stephens, A. and Evans, T.R.J. (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer, 49(4), pp. 782-789. (doi:10.1016/j.ejca.2012.09.036)

Karim, S.A., Creedon, H., Patel, H., Carragher, N.O., Morton, J.P. , Muller, W.J., Evans, T.R.J. , Gusterson, B., Sansom, O.J. and Brunton, V.G. (2013) Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. Journal of Pathology, 230(4), pp. 430-440. (doi:10.1002/path.4202)

Lassen, U. et al. (2013) Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. Cancer Chemotherapy and Pharmacology, 71(2), pp. 543-549. (doi:10.1007/s00280-012-2038-0)

Nobis, M. et al. (2013) Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of Src in pancreatic cancer. Cancer Research, 73(15), pp. 4674-4686. (doi:10.1158/0008-5472.CAN-12-4545)

2012

Cairney, C.J., Bilsland, A.E. , Evans, T.R.J. , Roffey, J., Bennett, D.C., Narita, M., Torrance, C. and Keith, W.N. (2012) Cancer cell senescence: a new frontier in drug development. Drug Discovery Today, 17(5-6), pp. 269-276. (doi:10.1016/j.drudis.2012.01.019)

Jamieson, N. B. , Morran, D. C., Morton, J. P., Ali, A., Dickson, E. J., Carter, C. R., Sansom, O. J. , Evans, T. R. J. , McKay, C. J. and Oien, K. A. (2012) MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clinical Cancer Research, 18(2), pp. 534-545. (doi:10.1158/1078-0432.CCR-11-0679)

Anthoney, D.A. et al. (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer, 12(536), (doi:10.1186/1471-2407-12-536)

Olmos, D. et al. (2012) Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. Journal of Clinical Oncology, 30(9), pp. 996-1004. (doi:10.1200/JCO.2010.34.5074)

2011

Venugopal, B. and Evans, T.R.J. (2011) Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics. Current Medicinal Chemistry, 18(11), pp. 1658-1671.

Lolkema, M. P. et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clinical Cancer Research, 17(3), pp. 581-588. (doi:10.1158/1078-0432.CCR-10-2159)

Boss, D.S., Glen, H., Beijnen, J.H., de Jong, D., Wanders, J., Evans, T.R.J. and Schellens, J. H.M. (2011) Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. Tumori, 97(1), pp. 109-14.

Leijen, S., Soetekouw, P.M.M.B., Evans, T.R.J. , Nicolson, M., Schellens, J.H.M., Learoyd, M., Grinsted, L., Zazulina, V., Pwint, T. and Middleton, M. (2011) A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 68(6), pp. 1619-1628. (doi:10.1007/s00280-011-1732-7)

Steele, N.L., Plumb, J.A., Vidal, L., Tjørnelund, J., Knoblauch, P., Buhl-Jensen, P., Molife, R., Brown, R., de Bono, J. S. and Evans, T.R.J. (2011) Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemotherapy and Pharmacology, 67(6), pp. 1273-1279. (doi:10.1007/s00280-010-1419-5)

Venugopal, B. and Evans, T.R.J. (2011) Gemcitabine elaidate cytotoxic agent oncolytic. Drugs of the Future, 36(6), pp. 427-432.

2010

Mansi, J. L. et al. (2010) Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study. Breast Cancer Research and Treatment, 122(3), pp. 787-794. (doi:10.1007/s10549-010-0989-6)

Morton, J.P. et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(1), pp. 246-251. (doi:10.1073/pnas.0908428107)

Morton, J. et al. (2010) LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology, 139(2), 586-597.e6. (doi:10.1053/j.gastro.2010.04.055)

Morton, J.P. et al. (2010) Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 139(1), pp. 292-303. (doi:10.1053/j.gastro.2010.03.034)

2009

Demetri, G. D., Lo Russo, P., MacPherson, I. R.J. , Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agarwal, S., Voi, M. and Evans, T.R. J. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15(9), pp. 6232-6240. (doi:10.1158/1078-0432.CCR-09-0224)

MacPherson, I.R.J. and Evans, T.R.J. (2009) New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009(1), pp. 1-18. (doi:10.2147/BCTT.S6127)

Scott, L., Evans, T., Cassidy, J., Harden, S., Paul, J., Ullah, R., O'Brien, V. and Brown, R. (2009) Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. British Journal of Cancer, 101(3), pp. 410-417. (doi:10.1038/sj.bjc.6605175)

Venugopal, B. and Evans, T.R.J. (2009) Coexistent malignant melanoma and renal cell carcinoma. Tumori, 95(4), pp. 518-520.

Braidwood, L., Dunn, P., Hardy, S., Evans, T. and Brown, S. (2009) Antitumor Activity of a Selectively Replication Competent Herpes Simplex Virus (HSV) with Enzyme Prodrug Therapy. Anticancer Research, 29(6), pp. 2159-2166.

Graham, J.S., Falk, S., Samuel, L.M., Cendros, J.M. and Evans, T.R.J. (2009) A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. Cancer Chemotherapy and Pharmacology, 63(5), pp. 945-952. (doi:10.1007/s00280-008-0795-6)

Scott, L. et al. (2009) A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology, 63(2), pp. 363-370. (doi:10.1007/s00280-008-0746-2)

Koutras, A., Giannopoulou, E., Kritikou, I., Antonacopoulou, A., Evans, T.R.J. , Papavassiliou, A.G. and Kalofonos, H. (2009) Antiproliferative effect of exemestane in lung cancer cells. Molecular Cancer, 8, p. 109. (doi:10.1186/1476-4598-8-109)

2008

Roxburgh, P. and Evans, T. (2008) Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy, 25(11), pp. 1089-1104. (doi:10.1007/s12325-008-0113-z)

Oien, K. and Evans, T. (2008) Raising the profile of cancer of unknown primary. Journal of Clinical Oncology, 26(27), pp. 4373-4375. (doi:10.1200/JCO.2008.17.6156)

Sarker, D. et al. (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clinical Cancer Research, 14(7), pp. 2075-2081. (doi:10.1158/1078-0432.CCR-07-1466)

Jones, R., Hawkins, R., Eatock, M., Ferry, D., Eskens, F., Wilke, H. and Evans, T. (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 61(3), pp. 435-441. (doi:10.1007/s00280-007-0486-8)

Steele, N. L. et al. (2008) A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors. Clinical Cancer Research, 14(3), p. 804. (doi:10.1158/1078-0432.CCR-07-1786)

Holmes, W., Maclellan, S., Condon, B., Dufes, C., Evans, T. , Uchegbu, I. and Schatzlein, A. (2008) High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil. Physics in Medicine and Biology, 53(2), pp. 505-513. (doi:10.1088/0031-9155/53/2/015)

Koutras, A., Mastronikolis, N., Evans, T., Papadeas, E., Makatsoris, T. and Kalofonos, H. (2008) Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. Acta Oncologica, 47(6), pp. 1171-1173. (doi:10.1080/02841860802213328)

2007

Guo, X., Evans, T.R.J. , Somanath, S., Armesilla, A.L., Darling, J.L., Schatzlein, A., Cassidy, J. and Wang, W. (2007) In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines. British Journal of Cancer, 97(6), pp. 745-754. (doi:10.1038/sj.bjc.6603930)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi:10.2174/1874079000701010009)

Oien, K.A., Dennis, J.L. and Evans, T.R.J. (2007) Metastatic adenocarcinoma of unknown origin. In: Kirkham, N. and Shepherd, N.A. (eds.) Progress in Pathology. Cambridge University Press: Cambridge, UK, pp. 135-162. ISBN 9780521694599

Oien, K.A., Stewart, I. and Evans, T.R.J. (2007) Unknown primary. In: Alison, M. (ed.) Cancer Handbook. John Wiley: Chichester, UK. ISBN 9780470018521

2006

Serrels, A., MacPherson, I.R.J. , Evans, T.R.J. , Lee, F.Y., Clark, E.A., Sansom, O.J. , Ashton, G.H., Frame, M.C. and Brunton, V.G. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Molecular Cancer Therapeutics, 5(12), pp. 3014-3022. (doi:10.1158/1535-7163.MCT-06-0382)

Evans, T. (2006) Docetaxel as neoadjuvant therapy in early-stage or locally advanced breast cancer. A view point by T R Jeffry Evans. American Journal of Cancer, 5(3), pp. 207-208.

Glen, H. and Evans, T.R.J. (2006) Vitamin D analogues as anti-cancer therapies. In: Stolzt, V.D. (ed.) Vitamin D: New Research. Nova Science: New York, USA, pp. 169-179. ISBN 9781600210006

2005

Evans, T. et al. (2005) Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study. Journal of Clinical Oncology, 23(13), pp. 2988-2995. (doi:10.1200/JCO.2005.06.156)

Evans, T. (2005) Evaluation of novel agents in pancreatic cancer. Salud I Ciencia, 13, pp. 10-13.

2004

Jodrell, D. et al. (2004) Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesopliageal adenocarcinoma. European Journal of Cancer, 40(12), pp. 1872-1877. (doi:10.1016/j.ejca.2004.04.032)

Johnston, S. et al. (2004) A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer Chemotherapy and Pharmacology, 53(4), pp. 341-348. (doi:10.1007/s00280-003-0733-6)

Mackay, H., Hoekstra, R., Eskens, F., Loos, W., Crawford, D., Voi, M., van Vreckem, A., Evans, T. and Verweij, J. (2004) A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors. Clinical Cancer Research, 10, pp. 2636-2644. (doi:10.1158/1078-0432.CCR-03-0327)

White, J., Marshall, D., Seywright, M. and Evans, T. (2004) Primary amyloidosis of the breast associated with invasive breast cancer. Oncology Reports, 11(4), pp. 761-763.

Evans, T.R.J. and Keith, W.N. (2004) Intra-Peritoneal Administration of Genetic Therapies: promises and pitfalls. Minerva Ginecologica, 56(6), pp. 529-538.

Keith, W. , Bilsland, A. , Hardie, M. and Evans, T. (2004) Drug Insight: cancer cell immortality - telomerase as a target for novel cancer gene therapies. Nature Clinical Practice Oncology, 1(2), pp. 88-96. (doi:10.1038/ncponc0044)

Scott, L. and Evans, T. (2004) Novel Cancer Therapeutics: Recent advances and future strategies. National Association of Primary Care Review, Spring, pp. 126-131.

2003

Dalhoff, K. et al. (2003) A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. British Journal of Cancer, 89(2), pp. 252-257. (doi:10.1038/sj.bjc.6601104)

White, J., MacPherson, I. and Evans, T. (2003) Auto-immune neutropenia occurring in association with malignant melanoma. Oncology Reports, 10(1), pp. 249-251.

Bilsland, A.E. , Anderson, C.J., Fletcher-Monaghan, A.J., McGregor, F., Evans, T.R.J. , Ganly, I., Knox, R.J., Plumb, J.A. and Keith, W.N. (2003) Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene, 22(3), pp. 370-380. (doi:10.1038/sj.onc.1206168)

Evans, T.R.J. (2003) Adjuvant systemic therapy. In: Rayter, Z. and Mansi, J. (eds.) Medical Therapy of Breast Cancer. Cambridge University Press: Cambridge, UK, pp. 153-177. ISBN 9780521496322

2002

Cameron, D. et al. (2002) Block sequential adriamycin CMF - optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? British Journal of Cancer, 87(12), pp. 1365-1369. (doi:10.1038/sj.bjc.6600660)

Evans, T. , Pentheroudakis, G., Paul, J. , McInnes, A., Blackie, R., Raby, N., Morrison, R., Fullarton, G., Soukop, M. and McDonald, A. (2002) A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Annals of Oncology, 13(9), pp. 1469-1478. (doi:10.1093/annonc/mdf243)

Licitra, L., Spinazze, S., Doci, R., Evans, T. , Tanum, G. and Ducreux, M. (2002) Cancer of the anal region. Critical Reviews in Oncology/Hematology, 43, pp. 77-92.

Diaz-Rubio, E., Evans, T. , Tabernero, J., Cassidy, J., Sastre, J., Eatock, M., Bisset, D., Regueiro, P. and Baselga, J. (2002) Capecitabine (Xeloda (R)) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Annals of Oncology, 13(4), pp. 558-565. (doi:10.1093/annonc/mdf065)

Evans, T. , Colston, K., Lofts, F., Cunningham, D., Anthoney, D., Gogas, H., de Bono, J., Hamberg, K., Skov, T. and Mansi, J. (2002) A phase II trial of the vitamin D analogue Seocalcitol (EB 1089) in patients with inoperable pancreatic cancer. British Journal of Cancer, 86(5), pp. 680-685. (doi:10.1038/sj/bjc/6600162)

Evans, T. and Keith, W. (2002) Telomerase and the senescence-like phenotype in cancer progression. Gastrointestinal Cancer Abstracts, 8, pp. 2-5.

Keith, W.N. , Bilsland, A. , Evans, T.R.J. and Glasspool, R.M. (2002) Telomerase-Directed Molecular Therapeutics. Expert Reviews in Molecular Medicine(4), pp. 1-25. (doi:10.1017/S1462399402004507)

Vasey, P.A. and Evans, T.R.J. (2002) Principles of chemotherapy and drug development. In: Price, P. and Sikora, K. (eds.) Treatment of Cancer. Arnold: London, UK, pp. 103-129. ISBN 9780340759646

2001

Mackay, H. et al. (2001) A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. Annals of Oncology, 12(10), pp. 1407-1410. (doi:10.1023/A:1012552823543)

Evans, T. (2001) Vaccine therapy for cancer - fact or fiction? Proceedings of the Royal College of Physicians of Edinburgh, 31, pp. 9-16.

Keith, W.N. , Evans, T.R.J. and Glasspool, R.M. (2001) Telomerase and cancer: time to move from a promising target to a clinical reality. Journal of Pathology, 195(4), pp. 404-414. (doi:10.1002/path.1001)

Plumb, J.A., Bilsland, A. , Kakani, R., Zhao, J.Q., Glasspool, R.M., Knox, R.J., Evans, T.R.J. and Keith, W.N. (2001) Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene, 20(53), pp. 7797-7803.

This list was generated on Tue Dec 10 15:56:44 2019 GMT.
Number of items: 121.

Articles

Jones, R. L. et al. (2019) Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European Journal of Cancer, 120, pp. 132-139. (doi:10.1016/j.ejca.2019.07.024) (PMID:31522033)

Naumann, R. W. et al. (2019) Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial. Journal of Clinical Oncology, (Accepted for Publication)

Reader, C. S. et al. (2019) The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, (doi:10.1002/path.5320) (PMID:31259422) (Early Online Publication)

Evans, T. R. J. et al. (2019) Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. British Journal of Cancer, (doi:10.1038/s41416-019-0506-6) (Early Online Publication)

Neves, K. B. , Rios, F. J. , Jones, R. , Evans, T. R. J. , Montezano, A. C. and Touyz, R. M. (2019) Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury. Cardiovascular Research, 115(5), pp. 978-988. (doi:10.1093/cvr/cvz021) (PMID:30753341) (PMCID:PMC6452312)

Conway, J. R.W., Herrmann, D., Evans, T.R. J. , Morton, J. P. and Timpson, P. (2019) Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut, 68(4), pp. 742-758. (doi:10.1136/gutjnl-2018-316822) (PMID:30396902) (PMCID:PMC6580874)

Twelves, C. et al. (2019) A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer, 120(6), pp. 579-586. (doi:10.1038/s41416-018-0366-5) (PMID:30783204) (PMCID:PMC6461928)

Anderson, R. L. et al. (2019) A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 16(3), pp. 185-204. (doi:10.1038/s41571-018-0134-8) (PMID:30514977)

Evans, T.R. J. et al. (2019) Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. British Journal of Cancer, (doi:10.1038/s41416-019-0377-x)

Janjigian, Y. Y. et al. (2018) CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. Journal of Clinical Oncology, 36(28), pp. 2836-2844. (doi:10.1200/JCO.2017.76.6212) (PMID:30110194) (PMCID:PMC6161834)

Lindsay, C. R. et al. (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3(6), e000408. (doi:10.1136/esmoopen-2018-000408) (PMID:30233821) (PMCID:PMC6135448)

Basu, B. et al. (2018) Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology, 29(9), pp. 1918-1925. (doi:10.1093/annonc/mdy245) (PMID:30016392) (PMCID:PMC6158767)

Krol, I. et al. (2018) Detection of circulating tumor cell clusters in human glioblastoma. British Journal of Cancer, 119, pp. 487-491. (doi:10.1038/s41416-018-0186-7) (PMID:30065256)

Baxter, M.A., Glen, H. and Evans, T.R.J. (2018) Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma. Future Oncology, 14(20), pp. 2021-2029. (doi:10.2217/fon-2017-0689) (PMID:29783903)

Candido, J. B. et al. (2018) CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Reports, 23(5), pp. 1448-1460. (doi:10.1016/j.celrep.2018.03.131) (PMID:29719257)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R. and Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicological Sciences, 163(1), pp. 293-306. (doi:10.1093/toxsci/kfy035) (PMID:29462473) (PMCID:PMC5920327)

Carvajal, R. D. et al. (2018) Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicentre, randomised trial (SUMIT). Journal of Clinical Oncology, 36(12), pp. 1232-1239. (doi:10.1200/JCO.2017.74.1090) (PMID:29528792)

Kudo, M. et al. (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 391(10126), pp. 1163-1173. (doi:10.1016/S0140-6736(18)30207-1) (PMID:29433850)

Marchetti, C. et al. (2018) Targeting multiple effector pathways in pancreatic ductal adenocarcinoma with a G-quadruplex-binding small molecule. Journal of Medicinal Chemistry, 61(6), pp. 2500-2517. (doi:10.1021/acs.jmedchem.7b01781) (PMID:29356532)

Cook, N. et al. (2018) A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 118(6), pp. 793-801. (doi:10.1038/bjc.2017.495) (PMID:29438372) (PMCID:PMC5877439)

Wilson, R. A.M., Evans, T.R. J. , Fraser, A. R. and Nibbs, R. J.B. (2018) Immune checkpoint inhibitors: new strategies to checkmate cancer. Clinical and Experimental Immunology, 191(2), pp. 133-148. (doi:10.1111/cei.13081) (PMID:29139554)

Meyer, T. et al. (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterology and Hepatology, 2(8), pp. 565-575. (doi:10.1016/S2468-1253(17)30156-5) (PMID:28648803)

de la Cruz-Merino, L. et al. (2017) Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of Translational Medicine, 15, 146. (doi:10.1186/s12967-017-1246-0) (PMID:28646893) (PMCID:PMC5483259)

Vennin, C. et al. (2017) Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9(384), eaai8504. (doi:10.1126/scitranslmed.aai8504) (PMID:28381539) (PMCID:PMC5777504)

Wilson, R. H. et al. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116(884), (doi:10.1038/bjc.2017.36) (PMID:28222073)

Evans, T.R.J. et al. (2017) Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Annals of Oncology, 28(2), pp. 354-361. (doi:10.1093/annonc/mdw607) (PMID:27998964)

Soria, J.C. et al. (2016) A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Annals of Oncology, 27(12), pp. 2268-2274. (doi:10.1093/annonc/mdw427) (PMID:27733373)

Driscoll, D. R. et al. (2016) mTORC2 signaling drives the development and progression of pancreatic cancer. Cancer Research, 76(23), pp. 6911-6923. (doi:10.1158/0008-5472.CAN-16-0810) (PMID:27758884)

Edeline, J. et al. (2016) A multicenter comparison between Child Pugh and ALBI scores in patients treated with sorafenib for hepatocellular carcinoma. Liver International, 36(2), pp. 1821-1828. (doi:10.1111/liv.13170) (PMID:27214151)

Jamieson, D. et al. (2016) A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 68, pp. 1-10. (doi:10.1016/j.ejca.2016.08.026) (PMID:27693888)

Propper, D., Jones, K., Anthoney, D. A., Mansoor, W., Ford, D., Eatock, M., Agarwal, R., Inatani, M., Saito, M. and Evans, T.R. J. (2016) Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. BMC Cancer, 16, 779. (PMID:27724887) (PMCID:PMC5057500)

Zhu, A. X. et al. (2016) Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with Sorafenib with or without Erlotinib in the SEARCH Trial. Clinical Cancer Research, 22(19), pp. 4870-4879. (doi:10.1158/1078-0432.CCR-15-2883) (PMID:27220960)

Aparicio, T., Zaanan, A., Mary, F., Afchain, P., Manfredi, S. and Evans, T. R. J. (2016) Small bowel adenocarcinoma. Gastroenterology Clinics of North America, 45(3), pp. 447-457. (doi:10.1016/j.gtc.2016.04.004) (PMID:27546842)

Bilsland, A. E. , Spiliopoulou, P. and Evans, T.R. J. (2016) Virotherapy: cancer gene therapy at last? F1000Research, 5, 2105. (doi:10.12688/f1000research.8211.1) (PMID:27635234) (PMCID:PMC5007754)

Antonia, S. J. et al. (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncology, 17(7), pp. 883-895. (doi:10.1016/S1470-2045(16)30098-5) (PMID:27269741)

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29(6), pp. 832-845. (doi:10.1016/j.ccell.2016.04.014) (PMID:27265504) (PMCID:PMC4912354)

Milojkovic Kerklaan, B. et al. (2016) A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Investigational New Drugs, 34(3), pp. 329-337. (doi:10.1007/s10637-016-0344-9) (PMID:27039386)

Graham, J.S., Boyd, K., Coxon, F.Y., Wall, L.R., Eatock, M.M., Maughan, T.S., Highley, M., Soulis, E., Conway, F. and Evans, T. (2016) A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Research Notes, 9(161), (doi:10.1186/s13104-015-1778-4) (PMID:26969121) (PMCID:PMC4788848)

Erami Rud Majani, Z. et al. (2016) Intravital FRAP imaging using an E-cadherin-GFP mouse reveals disease- and drug-dependent dynamic regulation of cell-cell junctions in live tissue. Cell Reports, 14(1), pp. 152-167. (doi:10.1016/j.celrep.2015.12.020) (PMID:26725115)

Carotenuto, P. et al. (2016) Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 66(7), pp. 1268-1277. (doi:10.1136/gutjnl-2016-312278) (PMID:27618837) (PMCID:PMC5530482)

Venugopal, B., Awada, A., Evans, T.R.J. , Dueland, S., Hendlisz, A., Rasch, W., Hernes, K., Hagen, S. and Aamdal, S. (2015) A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 76(4), pp. 785-792. (doi:10.1007/s00280-015-2846-0) (PMID:26289594)

Steele, C. et al. (2015) CXCR2 inhibition suppresses acute and chronic pancreatic inflammation. Journal of Pathology, 237(1), pp. 85-97. (doi:10.1002/path.4555) (PMID:25950520)

Zhu, A.X. et al. (2015) SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, 33(6), pp. 559-566. (doi:10.1200/JCO.2013.53.7746) (PMID:25547503)

Evans, T. J. (2015) Small colony variants of Pseudomonas aeruginosa in chronic bacterial infection of the lung in cystic fibrosis. Future Microbiology, 10(2), pp. 231-239. (doi:10.2217/fmb.14.107) (PMID:25689535)

Puzanov, I. et al. (2015) A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clinical Cancer Research, 21(4), pp. 701-711. (doi:10.1158/1078-0432.CCR-14-0303) (PMID:25212606)

Hartmann, D., von Figura, G., Song, Z., Harden, S., Scott, L. C., Evans, T. J. , Rudolph, K. L., Bilsland, A. E. and Keith, W. N. (2015) PlasmaN-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome. Future Oncology, 11(2), pp. 193-203. (doi:10.2217/fon.14.166)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

Monsieurs, K. G. et al. (2015) European Resuscitation Council Guidelines for Resuscitation 2015. Section 1. Executive summary. Resuscitation, 95, pp. 1-80. (doi:10.1016/j.resuscitation.2015.07.038) (PMID:26477410)

Moreno Garcia, V. et al. (2014) Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) collaboration study. Clinical Cancer Research, 20(22), pp. 5663-5671. (doi:10.1158/1078-0432.CCR-14-0719)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi:10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Roxburgh, P. , Lumsden, G. R., Paul, J. , Harden, S., Sweeting, L., James, A., Crellin, A., Morrison, R., Evans, T. R. J. and McDonald, A. C. (2014) A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 74(1), pp. 131-139. (doi:10.1007/s00280-014-2470-4) (PMID:24819683)

Middleton, G. et al. (2014) Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, 15(8), pp. 829-840. (doi:10.1016/S1470-2045(14)70236-0)

Chang, D. K. , Grimmond, S. M., Evans, T. R.J. and Biankin, A. V. (2014) Mining the genomes of exceptional responders. Nature Reviews Cancer, 14(5), pp. 291-292. (doi:10.1038/nrc3723) (PMID:25688402)

Poplin, E. et al. (2013) Randomized, multicenter, phase 2 study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. Journal of Clinical Oncology, 31(35), pp. 4453-4461. (doi:10.1200/JCO.2013.51.0826)

Venugopal, B. et al. (2013) A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clinical Cancer Research, 19(15), pp. 4262-4272. (doi:10.1158/1078-0432.CCR-13-0312)

Steele, C.W., Jamieson, N.B. , Evans, T.R.J. , McKay, C.J., Sansom, O.J. , Morton, J. and Carter, C.R. (2013) Exploiting inflammation for therapeutic gain in pancreatic cancer. British Journal of Cancer, 108(5), pp. 997-1003. (doi:10.1038/bjc.2013.24)

Macpherson, I.R. , Poondru, S., Simon, G.R., Gedrich, R., Brock, K., Hopkins, C.A., Stewart, K., Stephens, A. and Evans, T.R.J. (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer, 49(4), pp. 782-789. (doi:10.1016/j.ejca.2012.09.036)

Karim, S.A., Creedon, H., Patel, H., Carragher, N.O., Morton, J.P. , Muller, W.J., Evans, T.R.J. , Gusterson, B., Sansom, O.J. and Brunton, V.G. (2013) Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. Journal of Pathology, 230(4), pp. 430-440. (doi:10.1002/path.4202)

Lassen, U. et al. (2013) Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. Cancer Chemotherapy and Pharmacology, 71(2), pp. 543-549. (doi:10.1007/s00280-012-2038-0)

Nobis, M. et al. (2013) Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of Src in pancreatic cancer. Cancer Research, 73(15), pp. 4674-4686. (doi:10.1158/0008-5472.CAN-12-4545)

Cairney, C.J., Bilsland, A.E. , Evans, T.R.J. , Roffey, J., Bennett, D.C., Narita, M., Torrance, C. and Keith, W.N. (2012) Cancer cell senescence: a new frontier in drug development. Drug Discovery Today, 17(5-6), pp. 269-276. (doi:10.1016/j.drudis.2012.01.019)

Jamieson, N. B. , Morran, D. C., Morton, J. P., Ali, A., Dickson, E. J., Carter, C. R., Sansom, O. J. , Evans, T. R. J. , McKay, C. J. and Oien, K. A. (2012) MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clinical Cancer Research, 18(2), pp. 534-545. (doi:10.1158/1078-0432.CCR-11-0679)

Anthoney, D.A. et al. (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer, 12(536), (doi:10.1186/1471-2407-12-536)

Olmos, D. et al. (2012) Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. Journal of Clinical Oncology, 30(9), pp. 996-1004. (doi:10.1200/JCO.2010.34.5074)

Venugopal, B. and Evans, T.R.J. (2011) Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics. Current Medicinal Chemistry, 18(11), pp. 1658-1671.

Lolkema, M. P. et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clinical Cancer Research, 17(3), pp. 581-588. (doi:10.1158/1078-0432.CCR-10-2159)

Boss, D.S., Glen, H., Beijnen, J.H., de Jong, D., Wanders, J., Evans, T.R.J. and Schellens, J. H.M. (2011) Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. Tumori, 97(1), pp. 109-14.

Leijen, S., Soetekouw, P.M.M.B., Evans, T.R.J. , Nicolson, M., Schellens, J.H.M., Learoyd, M., Grinsted, L., Zazulina, V., Pwint, T. and Middleton, M. (2011) A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 68(6), pp. 1619-1628. (doi:10.1007/s00280-011-1732-7)

Steele, N.L., Plumb, J.A., Vidal, L., Tjørnelund, J., Knoblauch, P., Buhl-Jensen, P., Molife, R., Brown, R., de Bono, J. S. and Evans, T.R.J. (2011) Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemotherapy and Pharmacology, 67(6), pp. 1273-1279. (doi:10.1007/s00280-010-1419-5)

Venugopal, B. and Evans, T.R.J. (2011) Gemcitabine elaidate cytotoxic agent oncolytic. Drugs of the Future, 36(6), pp. 427-432.

Mansi, J. L. et al. (2010) Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study. Breast Cancer Research and Treatment, 122(3), pp. 787-794. (doi:10.1007/s10549-010-0989-6)

Morton, J.P. et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(1), pp. 246-251. (doi:10.1073/pnas.0908428107)

Morton, J. et al. (2010) LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology, 139(2), 586-597.e6. (doi:10.1053/j.gastro.2010.04.055)

Morton, J.P. et al. (2010) Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 139(1), pp. 292-303. (doi:10.1053/j.gastro.2010.03.034)

Demetri, G. D., Lo Russo, P., MacPherson, I. R.J. , Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agarwal, S., Voi, M. and Evans, T.R. J. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15(9), pp. 6232-6240. (doi:10.1158/1078-0432.CCR-09-0224)

MacPherson, I.R.J. and Evans, T.R.J. (2009) New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009(1), pp. 1-18. (doi:10.2147/BCTT.S6127)

Scott, L., Evans, T., Cassidy, J., Harden, S., Paul, J., Ullah, R., O'Brien, V. and Brown, R. (2009) Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. British Journal of Cancer, 101(3), pp. 410-417. (doi:10.1038/sj.bjc.6605175)

Venugopal, B. and Evans, T.R.J. (2009) Coexistent malignant melanoma and renal cell carcinoma. Tumori, 95(4), pp. 518-520.

Braidwood, L., Dunn, P., Hardy, S., Evans, T. and Brown, S. (2009) Antitumor Activity of a Selectively Replication Competent Herpes Simplex Virus (HSV) with Enzyme Prodrug Therapy. Anticancer Research, 29(6), pp. 2159-2166.

Graham, J.S., Falk, S., Samuel, L.M., Cendros, J.M. and Evans, T.R.J. (2009) A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. Cancer Chemotherapy and Pharmacology, 63(5), pp. 945-952. (doi:10.1007/s00280-008-0795-6)

Scott, L. et al. (2009) A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology, 63(2), pp. 363-370. (doi:10.1007/s00280-008-0746-2)

Koutras, A., Giannopoulou, E., Kritikou, I., Antonacopoulou, A., Evans, T.R.J. , Papavassiliou, A.G. and Kalofonos, H. (2009) Antiproliferative effect of exemestane in lung cancer cells. Molecular Cancer, 8, p. 109. (doi:10.1186/1476-4598-8-109)

Roxburgh, P. and Evans, T. (2008) Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy, 25(11), pp. 1089-1104. (doi:10.1007/s12325-008-0113-z)

Oien, K. and Evans, T. (2008) Raising the profile of cancer of unknown primary. Journal of Clinical Oncology, 26(27), pp. 4373-4375. (doi:10.1200/JCO.2008.17.6156)

Sarker, D. et al. (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clinical Cancer Research, 14(7), pp. 2075-2081. (doi:10.1158/1078-0432.CCR-07-1466)

Jones, R., Hawkins, R., Eatock, M., Ferry, D., Eskens, F., Wilke, H. and Evans, T. (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 61(3), pp. 435-441. (doi:10.1007/s00280-007-0486-8)

Steele, N. L. et al. (2008) A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors. Clinical Cancer Research, 14(3), p. 804. (doi:10.1158/1078-0432.CCR-07-1786)

Holmes, W., Maclellan, S., Condon, B., Dufes, C., Evans, T. , Uchegbu, I. and Schatzlein, A. (2008) High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil. Physics in Medicine and Biology, 53(2), pp. 505-513. (doi:10.1088/0031-9155/53/2/015)

Koutras, A., Mastronikolis, N., Evans, T., Papadeas, E., Makatsoris, T. and Kalofonos, H. (2008) Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. Acta Oncologica, 47(6), pp. 1171-1173. (doi:10.1080/02841860802213328)

Guo, X., Evans, T.R.J. , Somanath, S., Armesilla, A.L., Darling, J.L., Schatzlein, A., Cassidy, J. and Wang, W. (2007) In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines. British Journal of Cancer, 97(6), pp. 745-754. (doi:10.1038/sj.bjc.6603930)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi:10.2174/1874079000701010009)

Serrels, A., MacPherson, I.R.J. , Evans, T.R.J. , Lee, F.Y., Clark, E.A., Sansom, O.J. , Ashton, G.H., Frame, M.C. and Brunton, V.G. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Molecular Cancer Therapeutics, 5(12), pp. 3014-3022. (doi:10.1158/1535-7163.MCT-06-0382)

Evans, T. (2006) Docetaxel as neoadjuvant therapy in early-stage or locally advanced breast cancer. A view point by T R Jeffry Evans. American Journal of Cancer, 5(3), pp. 207-208.

Evans, T. et al. (2005) Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study. Journal of Clinical Oncology, 23(13), pp. 2988-2995. (doi:10.1200/JCO.2005.06.156)

Evans, T. (2005) Evaluation of novel agents in pancreatic cancer. Salud I Ciencia, 13, pp. 10-13.

Jodrell, D. et al. (2004) Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesopliageal adenocarcinoma. European Journal of Cancer, 40(12), pp. 1872-1877. (doi:10.1016/j.ejca.2004.04.032)

Johnston, S. et al. (2004) A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer Chemotherapy and Pharmacology, 53(4), pp. 341-348. (doi:10.1007/s00280-003-0733-6)

Mackay, H., Hoekstra, R., Eskens, F., Loos, W., Crawford, D., Voi, M., van Vreckem, A., Evans, T. and Verweij, J. (2004) A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors. Clinical Cancer Research, 10, pp. 2636-2644. (doi:10.1158/1078-0432.CCR-03-0327)

White, J., Marshall, D., Seywright, M. and Evans, T. (2004) Primary amyloidosis of the breast associated with invasive breast cancer. Oncology Reports, 11(4), pp. 761-763.

Evans, T.R.J. and Keith, W.N. (2004) Intra-Peritoneal Administration of Genetic Therapies: promises and pitfalls. Minerva Ginecologica, 56(6), pp. 529-538.

Keith, W. , Bilsland, A. , Hardie, M. and Evans, T. (2004) Drug Insight: cancer cell immortality - telomerase as a target for novel cancer gene therapies. Nature Clinical Practice Oncology, 1(2), pp. 88-96. (doi:10.1038/ncponc0044)

Scott, L. and Evans, T. (2004) Novel Cancer Therapeutics: Recent advances and future strategies. National Association of Primary Care Review, Spring, pp. 126-131.

Dalhoff, K. et al. (2003) A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. British Journal of Cancer, 89(2), pp. 252-257. (doi:10.1038/sj.bjc.6601104)

White, J., MacPherson, I. and Evans, T. (2003) Auto-immune neutropenia occurring in association with malignant melanoma. Oncology Reports, 10(1), pp. 249-251.

Bilsland, A.E. , Anderson, C.J., Fletcher-Monaghan, A.J., McGregor, F., Evans, T.R.J. , Ganly, I., Knox, R.J., Plumb, J.A. and Keith, W.N. (2003) Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene, 22(3), pp. 370-380. (doi:10.1038/sj.onc.1206168)

Cameron, D. et al. (2002) Block sequential adriamycin CMF - optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? British Journal of Cancer, 87(12), pp. 1365-1369. (doi:10.1038/sj.bjc.6600660)

Evans, T. , Pentheroudakis, G., Paul, J. , McInnes, A., Blackie, R., Raby, N., Morrison, R., Fullarton, G., Soukop, M. and McDonald, A. (2002) A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Annals of Oncology, 13(9), pp. 1469-1478. (doi:10.1093/annonc/mdf243)

Licitra, L., Spinazze, S., Doci, R., Evans, T. , Tanum, G. and Ducreux, M. (2002) Cancer of the anal region. Critical Reviews in Oncology/Hematology, 43, pp. 77-92.

Diaz-Rubio, E., Evans, T. , Tabernero, J., Cassidy, J., Sastre, J., Eatock, M., Bisset, D., Regueiro, P. and Baselga, J. (2002) Capecitabine (Xeloda (R)) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Annals of Oncology, 13(4), pp. 558-565. (doi:10.1093/annonc/mdf065)

Evans, T. , Colston, K., Lofts, F., Cunningham, D., Anthoney, D., Gogas, H., de Bono, J., Hamberg, K., Skov, T. and Mansi, J. (2002) A phase II trial of the vitamin D analogue Seocalcitol (EB 1089) in patients with inoperable pancreatic cancer. British Journal of Cancer, 86(5), pp. 680-685. (doi:10.1038/sj/bjc/6600162)

Evans, T. and Keith, W. (2002) Telomerase and the senescence-like phenotype in cancer progression. Gastrointestinal Cancer Abstracts, 8, pp. 2-5.

Keith, W.N. , Bilsland, A. , Evans, T.R.J. and Glasspool, R.M. (2002) Telomerase-Directed Molecular Therapeutics. Expert Reviews in Molecular Medicine(4), pp. 1-25. (doi:10.1017/S1462399402004507)

Mackay, H. et al. (2001) A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. Annals of Oncology, 12(10), pp. 1407-1410. (doi:10.1023/A:1012552823543)

Evans, T. (2001) Vaccine therapy for cancer - fact or fiction? Proceedings of the Royal College of Physicians of Edinburgh, 31, pp. 9-16.

Keith, W.N. , Evans, T.R.J. and Glasspool, R.M. (2001) Telomerase and cancer: time to move from a promising target to a clinical reality. Journal of Pathology, 195(4), pp. 404-414. (doi:10.1002/path.1001)

Plumb, J.A., Bilsland, A. , Kakani, R., Zhao, J.Q., Glasspool, R.M., Knox, R.J., Evans, T.R.J. and Keith, W.N. (2001) Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene, 20(53), pp. 7797-7803.

Book Sections

Oien, K.A., Dennis, J.L. and Evans, T.R.J. (2007) Metastatic adenocarcinoma of unknown origin. In: Kirkham, N. and Shepherd, N.A. (eds.) Progress in Pathology. Cambridge University Press: Cambridge, UK, pp. 135-162. ISBN 9780521694599

Oien, K.A., Stewart, I. and Evans, T.R.J. (2007) Unknown primary. In: Alison, M. (ed.) Cancer Handbook. John Wiley: Chichester, UK. ISBN 9780470018521

Glen, H. and Evans, T.R.J. (2006) Vitamin D analogues as anti-cancer therapies. In: Stolzt, V.D. (ed.) Vitamin D: New Research. Nova Science: New York, USA, pp. 169-179. ISBN 9781600210006

Evans, T.R.J. (2003) Adjuvant systemic therapy. In: Rayter, Z. and Mansi, J. (eds.) Medical Therapy of Breast Cancer. Cambridge University Press: Cambridge, UK, pp. 153-177. ISBN 9780521496322

Vasey, P.A. and Evans, T.R.J. (2002) Principles of chemotherapy and drug development. In: Price, P. and Sikora, K. (eds.) Treatment of Cancer. Arnold: London, UK, pp. 103-129. ISBN 9780340759646

This list was generated on Tue Dec 10 15:56:44 2019 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • HUNTER: Hepatocellular Carcinoma Expediter Network
    Cancer Research UK
    2019 - 2019
     
  • Experimental Therapeutic Support
    Beatson West of Scotland Cancer Centre
    2018 - 2019
     
  • CDD Biomarkers Tender
    Cancer Research UK
    2017 - 2019
     
  • Developing new clinically relevant positron emission tomography (PET) probes in Glasgow
    Beatson Cancer Charity
    2017 - 2022
     
  • Precision Medicine Laboratory sequencing of patient tumour samples
    Beatson Cancer Charity
    2017 - 2022
     
  • CRUK Centre Renewal
    Cancer Research UK
    2017 - 2019
     
  • Glasgow ECMC
    Cancer Research UK
    2017 - 2019
     
  • Precision-Panc: a dynamic therapeutic development platform for pancreatic cancer
    Cancer Research UK
    2017 - 2019
     
  • Glasgow ECMC
    Chief Scientist Office
    2017 - 2018
     
  • A Phase Ib/IIa clinical trial of FAK inhibitor VS6063 in combination with anti-PD1/PDL1 therapy
    Cancer Research UK
    2016 - 2020
     
  • Glasgow Molecular Pathology (GMP) Node
    Medical Research Council
    2015 - 2019
     
  • Regulation of stem cell function during tissue homeostasis and transformation
    Wellcome Trust
    2015 - 2020
     
  • The William and Elizabeth Davies Charitable Foundation Clinical Research Fellow
    Royal College of Physicians and Surgeons of Glasgow
    2014 - 2017
     
  • A Phase I study of Olaparib in Combination with Chemo-Radiation in Locally Advanced Pancreatic Cancer.
    Cancer Research UK
    2014 - 2020
     
  • CR-UK Centre renewal
    Cancer Research UK
    2014 - 2017
     
  • The relationship between p53 mutation and inflammation in high-grade serous ovarian cancer
    Academy of Medical Sciences
    2014 - 2015
     
  • Telomerase Study
    Beatson West of Scotland Cancer Centre
    2014 - 2014
     
  • An examination of diagnostic and prognostic biomarkers in malignant pleural mesothelioma
    Chief Scientist Office
    2013 - 2018
     
  • Cancer Research UK Clinical Trials Unit - Core Programme Funding
    Cancer Research UK
    2013 - 2018
     
  • Stratified Medicine Clinical Hub
    Cancer Research UK
    2013 - 2013
     
  • TamiRCRT - Targeting microRNAs for ColoRectal Cancer Therapy
    European Commission
    2013 - 2017
     
  • In Vivo Optimization of Therapy in Pancreatic Ductal Adenocarcinoma.
    Beatson West of Scotland Cancer Centre
    2013 - 2014
     
  • Support of British Journal of Cancer Clinical Studies Editor
    Cancer Research UK
    2013 - 2019
     
  • Glioma Actively Personalized Vaccine Consortium (GAPVAC)
    European Commission
    2012 - 2016
     
  • Experimental Cancer Medicine Centre (ECMC)
    Chief Scientist Office
    2012 - 2017
     
  • Phase I/IIA Study of AZD4547 in Combination with Cisplatin and Capecitabine (CX)
    Cancer Research UK
    2011 - 2017
     
  • Investigating the role of CXCR2 in pancreatic inflammation and cancer.
    Wellcome Trust
    2011 - 2014
     
  • Stratified Medicine Phase One: Clinical Hubs - March 2011
    Cancer Research UK
    2011 - 2015
     
  • In vivo Evaluation of Src Kinase Inhibition as Adjuvant Therapy following Pancreatic Cancer Resection
    Pancreatic Cancer Research Fund
    2011 - 2013
     
  • Investigating the use of an EUS core biopsy needle versus a traditional FNA cytology aspiration technique in obtaining tumour tissue for diagnostic, IHC and kinome-signature analysis
    Cancer Research UK
    2010 - 2012
     
  • p53 mutation as a biomarker for response to anti-EGFR therapy in metastatic colorectal cancer
    Cancer Research UK
    2010 - 2012
     
  • Glasgow Cancer Research UK Centre (CORE)
    Cancer Research UK
    2010 - 2015
     
  • Investigating personalised therapy in mouse models of pancreatic cancer.
    Medical Research Council
    2010 - 2013
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2010 - 2018
     
  • The CUP-ONE trial - a multi-centre randomised phase II study comparing epirubcin, cisplatin and capecitabine with and without Erlotinib in c
    Cancer Research UK
    2009 - 2014
     
  • HER2 status of primary and metatastic gastric cancer - implications for therapy
    Scottish Executive Health Department
    2005 - 2006
     
  • Application of radio-isotope imaging and therapy in patients with breast carcinomas which express the sodium iodide symporter gene(V Hughes)
    Gunnar Nilsson Cancer Treatment Trust Fund
    2004 - 2006